Dimensional Fund Advisors’s SpringWorks Therapeutics SWTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-555,888
Closed -$24.5M 3330
2025
Q1
$24.5M Sell
555,888
-161,826
-23% -$7.45M 0.01% 1846
2024
Q4
$25.9M Sell
717,714
-7,403
-1% -$259K 0.01% 1877
2024
Q3
$23.2M Sell
725,117
-105,405
-13% -$3.94M 0.01% 1939
2024
Q2
$31.3M Sell
830,522
-75,214
-8% -$3.17M 0.01% 1730
2024
Q1
$44.6M Sell
905,736
-62,669
-6% -$2.9M 0.01% 1540
2023
Q4
$35.3M Sell
968,405
-42,964
-4% -$1.12M 0.01% 1669
2023
Q3
$23.4M Buy
1,011,369
+28,016
+3% +$766K 0.01% 1832
2023
Q2
$25.8M Buy
983,353
+187,890
+24% +$4.94M 0.01% 1795
2023
Q1
$20.5M Buy
795,463
+522,571
+191% +$15.3M 0.01% 1898
2022
Q4
$7.1K Buy
272,892
+181,050
+197% +$4.46M ﹤0.01% 2346
2022
Q3
$2.62M Sell
91,842
-61,158
-40% -$1.75M ﹤0.01% 2629
2022
Q2
$3.77M Sell
153,000
-42,539
-22% -$1.56M ﹤0.01% 2531
2022
Q1
$11M Buy
195,539
+3,296
+2% +$189K ﹤0.01% 2249
2021
Q4
$11.9M Sell
192,243
-3,593
-2% -$238K ﹤0.01% 2235
2021
Q3
$12.4M Buy
195,836
+120,323
+159% +$9.27M ﹤0.01% 2228
2021
Q2
$6.22M Buy
+75,513
New +$5.73M ﹤0.01% 2537

Other funds holding SWTX

Dimensional Fund Advisors's SWTX Position: Q2 2025 in Review

Dimensional Fund Advisors sold out of SpringWorks Therapeutics (SWTX) in Q2 2025, closing a stake of 555,888 shares — an estimated $24.5M sold.

Dimensional Fund Advisors first reported a position in SWTX in Q2 2021 and held it in 16 quarters. The position peaked at $44.6M in Q1 2024. 222 funds tracked by Wall St. Rank hold SWTX as of Q2 2025.

  • Dimensional Fund Advisors reported no remaining SpringWorks Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Dimensional Fund Advisors sold 555,888 SpringWorks Therapeutics shares in Q2 2025, an estimated $24.5M.
  • Dimensional Fund Advisors first reported a position in SpringWorks Therapeutics in Q2 2021 and held it in 16 quarters.
  • Dimensional Fund Advisors's SpringWorks Therapeutics position peaked at $44.6M in Q1 2024.
  • 222 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2025.

Based on Dimensional Fund Advisors's 13F filing for Q2 2025, filed 12 Aug 2025.